<ul>
<li><strong>MSD 拒绝行使 EVX-B2 开发的选择权</strong></li>
<li><strong>Evaxion 现在可以将 EVX-B2 转让给其他合作伙伴</strong></li>
<li><strong>Evaxion 对 EVX-B2 保持强烈信心，该疫苗在临床前研究中显示出对淋病的保护作用</strong></li>
<li><strong>Evaxion 的现金流不会受到影响，预计可持续到 2027 年下半年</strong></li>
</ul>
<p>丹麦哥本哈根，2025 年 12 月 19 日- Evaxion A/S（纳斯达克：EVAX）（“Evaxion”），一家专注于开发 AI-Immunology™驱动疫苗的临床阶段科技生物公司，已获悉 MSD（默克公司，位于美国新泽西州拉威）将不行使其对 Evaxion 淋病疫苗候选药物 EVX-B2 的选择权。因此，Evaxion 保留 EVX-B2 的全球权利，并将寻找其他潜在的许可合作伙伴。</p>
<p>今年早些时候，MSD 行使了对 Evaxion 另一款疫苗候选药物 EVX-B3 的选择权。Evaxion 有资格获得与 EVX-B3 开发相关的高达 5.92 亿美元的里程碑付款，以及净销售的特许权使用费。</p>
<p>淋病每年在全球感染超过 8000 万人。尽管经过数十年的研究，迄今尚未批准任何疫苗。临床前研究表明，EVX-B2 对淋病细菌具有保护作用。因此，它展示了 Evaxion 的 AI-Immunology™平台发现新型疫苗候选药物的潜力。</p>
<p>“虽然我们对 MSD 不行使其选择权的决定感到失望，但我们对 EVX-B2 项目仍然感到兴奋并承诺继续推进。迄今为止我们生成的数据令人鼓舞，强调了 EVX-B2 成为首个获批淋病疫苗的潜力，满足了一个重大的未满足医疗需求。我们现在将启动寻找 EVX-B2 其他合作伙伴的过程，” Evaxion 首席执行官 Helen Tayton-Martin 表示。</p>
<p>Evaxion 在其现金流展望中并未包括 MSD 可能对 EVX-B2 的许可。因此，MSD 的决定不会影响我们的现金流，预计仍可持续到 2027 年下半年。</p>
<p>MSD 的选择权是针对 EVX-B2 的蛋白质版本。此外，Evaxion 还在与 Afrigen Biologics 合作开发该候选药物的 mRNA 版本。</p>
<p><strong>联系信息</strong></p>
<p>Evaxion A/S</p>
<p>Mads Kronborg</p>
<p>副总裁，投资者关系与沟通</p>
<p>+45 53 54 82 96</p>
<p>mak@evaxion.ai</p>
<p><strong>关于 Evaxion</strong></p>
<p>Evaxion 是一家基于其 AI 平台 AI-Immunology™的先锋科技生物公司。Evaxion 的专有和可扩展的 AI 预测模型利用人工智能的力量解码人类免疫系统，并开发针对癌症、细菌疾病和病毒感染的新型免疫疗法。基于 AI-Immunology™，Evaxion 开发了一条临床阶段的肿瘤学新型个性化疫苗管线，以及一条针对高未满足医疗需求的细菌和病毒疾病的临床前传染病管线。Evaxion 致力于通过提供创新和针对性的治疗选择来改变患者的生活。有关 Evaxion 及其开创性的 AI-Immunology™平台和疫苗管线的更多信息，请访问我们的网站。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。诸如 “目标”、“相信”、“期望”、“希望”、“旨在”、“打算”、“可能”、“或许”、“预期”、“考虑”、“继续”、“估计”、“计划”、“潜力”、“预测”、“项目”、“将”、“可以”、“可能”、“应该”、“会”、“能够” 等词语及其他类似含义的词语和术语标识前瞻性声明。实际结果可能因各种因素而与这些前瞻性声明所指示的结果有实质性差异，包括但不限于与以下相关的风险：我们的财务状况和对额外资本的需求；我们的开发工作；我们产品开发活动及临床前和临床试验的成本和成功；利用我们的 AI 平台技术开发的任何获批药品的商业化，包括我们产品候选药物的市场接受率和程度；我们对第三方的依赖，包括临床测试和产品制造的进行；我们无法建立合作伙伴关系；政府监管；保护我们的知识产权；员工事务和管理增长；我们的 ADS 和普通股，国际经济、政治、法律、合规、社会和商业因素的影响，包括通货膨胀，以及其他重大地缘政治和宏观经济事件对我们业务的影响；以及影响我们业务运营和财务状况的其他不确定性。有关这些风险的进一步讨论，请参阅我们最近提交的 20-F 表格年报及其他向美国证券交易委员会（SEC）提交的文件，这些文件可在 <strong>www.sec.gov</strong> 上获取。除法律要求外，我们不承担更新任何前瞻性声明的义务。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVGc1TkNNME1ESXlPRFl3T1RNak1qSTFNakE0Tnc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVGc1TkNNME1ESXlPRFl3T1RNak1qSTFNakE0Tnc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NWMzZjVkMGItOGNiYS00OTgzLTkzN2EtZjAxN2VhMTExNjg4LTEyNjM2NDAtMjAyNS0xMi0xOS1lbg==/tiny/Evaxion.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NWMzZjVkMGItOGNiYS00OTgzLTkzN2EtZjAxN2VhMTExNjg4LTEyNjM2NDAtMjAyNS0xMi0xOS1lbg==/tiny/Evaxion.png"/></p>

EVAX

<p>Evaxion 保留其淋病疫苗候选药物 EVX-B2 的全球权利，因为 MSD 拒绝行使其开发选项。Evaxion 将寻求其他许可合作伙伴，同时保持对 EVX-B2 潜力的信心，因为前临床研究显示其对淋病具有保护作用。该决定不会影响 Evaxion 的现金流，预计可持续到 2027 年下半年。Evaxion 还与 Afrigen Biologics 一起开发 EVX-B2 的 mRNA 版本</p>

<ul>
<li><strong>MSD declines to exercise option for EVX-B2 development</strong></li>
<li><strong>Evaxion is now able to out-license EVX-B2 to another partner</strong></li>
<li><strong>Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studies</strong></li>
<li><strong>There is no impact on Evaxion’s cash runway which extends to the second half of 2027</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>MSD 拒绝行使 EVX-B2 开发的选择权</strong></li>
<li><strong>Evaxion 现在可以将 EVX-B2 转让给其他合作伙伴</strong></li>
<li><strong>Evaxion 对 EVX-B2 保持强烈信心，该疫苗在临床前研究中显示出对淋病的保护作用</strong></li>
<li><strong>Evaxion 的现金流不会受到影响，预计可持续到 2027 年下半年</strong></li>
</ul>
</div><p>COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed that MSD (tradename of Merck &amp; Co., Inc., Rahway, NJ, USA) will not exercise its option for Evaxion’s Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.</p>
<div class="lb-trans"><p>丹麦哥本哈根，2025 年 12 月 19 日- Evaxion A/S（纳斯达克：EVAX）（“Evaxion”），一家专注于开发 AI-Immunology™驱动疫苗的临床阶段科技生物公司，已获悉 MSD（默克公司，位于美国新泽西州拉威）将不行使其对 Evaxion 淋病疫苗候选药物 EVX-B2 的选择权。因此，Evaxion 保留 EVX-B2 的全球权利，并将寻找其他潜在的许可合作伙伴。</p>
</div><p>Earlier this year MSD exercised its option on a separate Evaxion vaccine candidate, EVX-B3. Evaxion is eligible for milestone payments up to $592 million associated with the development of EVX-B3, as well as royalties on net sales.</p>
<div class="lb-trans"><p>今年早些时候，MSD 行使了对 Evaxion 另一款疫苗候选药物 EVX-B3 的选择权。Evaxion 有资格获得与 EVX-B3 开发相关的高达 5.92 亿美元的里程碑付款，以及净销售的特许权使用费。</p>
</div><p>Gonorrhea infects more than 80 million people worldwide each year. Despite decades of research, no vaccine has been approved to date. Preclinical studies demonstrate that EVX-B2 protects against the Gonorrhea-bacteria. As such, it exemplifies the potential of Evaxion’s AI-Immunology™ platform to discover novel vaccine candidates.</p>
<div class="lb-trans"><p>淋病每年在全球感染超过 8000 万人。尽管经过数十年的研究，迄今尚未批准任何疫苗。临床前研究表明，EVX-B2 对淋病细菌具有保护作用。因此，它展示了 Evaxion 的 AI-Immunology™平台发现新型疫苗候选药物的潜力。</p>
</div><p>“While we are disappointed by MSD’s decision not to exercise its option, we remain excited by, and committed to, the EVX-B2 program. The data we have generated to date are encouraging and underscore EVX-B2’s potential to be the first approved vaccine for Gonorrhea, addressing a major unmet medical need. We will now initiate the process of finding another partner on EVX-B2,” says Helen Tayton-Martin, CEO at Evaxion.</p>
<div class="lb-trans"><p>“虽然我们对 MSD 不行使其选择权的决定感到失望，但我们对 EVX-B2 项目仍然感到兴奋并承诺继续推进。迄今为止我们生成的数据令人鼓舞，强调了 EVX-B2 成为首个获批淋病疫苗的潜力，满足了一个重大的未满足医疗需求。我们现在将启动寻找 EVX-B2 其他合作伙伴的过程，” Evaxion 首席执行官 Helen Tayton-Martin 表示。</p>
</div><p>Evaxion did not include a potential in-licensing of EVX-B2 by MSD in its cash-flow outlook. Thus, the decision by MSD does not impact our cash runway which still extends to the second half of 2027.</p>
<div class="lb-trans"><p>Evaxion 在其现金流展望中并未包括 MSD 可能对 EVX-B2 的许可。因此，MSD 的决定不会影响我们的现金流，预计仍可持续到 2027 年下半年。</p>
</div><p>MSD’s option was on the protein-based version of EVX-B2. Separately, Evaxion is also developing an mRNA-version of the candidate in collaboration with Afrigen Biologics.</p>
<div class="lb-trans"><p>MSD 的选择权是针对 EVX-B2 的蛋白质版本。此外，Evaxion 还在与 Afrigen Biologics 合作开发该候选药物的 mRNA 版本。</p>
</div><p><strong>Contact information</strong></p>
<div class="lb-trans"><p><strong>联系信息</strong></p>
</div><p>Evaxion A/S</p>
<div class="lb-trans"><p>Evaxion A/S</p>
</div><p>Mads Kronborg</p>
<div class="lb-trans"><p>Mads Kronborg</p>
</div><p>Vice President, Investor Relations &amp; Communication</p>
<div class="lb-trans"><p>副总裁，投资者关系与沟通</p>
</div><p>+45 53 54 82 96</p>
<div class="lb-trans"><p>+45 53 54 82 96</p>
</div><p>mak@evaxion.ai</p>
<div class="lb-trans"><p>mak@evaxion.ai</p>
</div><p><strong>About Evaxion</strong></p>
<div class="lb-trans"><p><strong>关于 Evaxion</strong></p>
</div><p>Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.</p>
<div class="lb-trans"><p>Evaxion 是一家基于其 AI 平台 AI-Immunology™的先锋科技生物公司。Evaxion 的专有和可扩展的 AI 预测模型利用人工智能的力量解码人类免疫系统，并开发针对癌症、细菌疾病和病毒感染的新型免疫疗法。基于 AI-Immunology™，Evaxion 开发了一条临床阶段的肿瘤学新型个性化疫苗管线，以及一条针对高未满足医疗需求的细菌和病毒疾病的临床前传染病管线。Evaxion 致力于通过提供创新和针对性的治疗选择来改变患者的生活。有关 Evaxion 及其开创性的 AI-Immunology™平台和疫苗管线的更多信息，请访问我们的网站。</p>
</div><p><strong>Forward-looking statement</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at <strong>www.sec.gov</strong>. We do not assume any obligation to update any forward-looking statements except as required by law.</p>
<div class="lb-trans"><p>本公告包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。诸如 “目标”、“相信”、“期望”、“希望”、“旨在”、“打算”、“可能”、“或许”、“预期”、“考虑”、“继续”、“估计”、“计划”、“潜力”、“预测”、“项目”、“将”、“可以”、“可能”、“应该”、“会”、“能够” 等词语及其他类似含义的词语和术语标识前瞻性声明。实际结果可能因各种因素而与这些前瞻性声明所指示的结果有实质性差异，包括但不限于与以下相关的风险：我们的财务状况和对额外资本的需求；我们的开发工作；我们产品开发活动及临床前和临床试验的成本和成功；利用我们的 AI 平台技术开发的任何获批药品的商业化，包括我们产品候选药物的市场接受率和程度；我们对第三方的依赖，包括临床测试和产品制造的进行；我们无法建立合作伙伴关系；政府监管；保护我们的知识产权；员工事务和管理增长；我们的 ADS 和普通股，国际经济、政治、法律、合规、社会和商业因素的影响，包括通货膨胀，以及其他重大地缘政治和宏观经济事件对我们业务的影响；以及影响我们业务运营和财务状况的其他不确定性。有关这些风险的进一步讨论，请参阅我们最近提交的 20-F 表格年报及其他向美国证券交易委员会（SEC）提交的文件，这些文件可在 <strong>www.sec.gov</strong> 上获取。除法律要求外，我们不承担更新任何前瞻性声明的义务。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVGc1TkNNME1ESXlPRFl3T1RNak1qSTFNakE0Tnc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0NTg5NCM0MDIyODYwOTMjMjI1MjA4Nw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NWMzZjVkMGItOGNiYS00OTgzLTkzN2EtZjAxN2VhMTExNjg4LTEyNjM2NDAtMjAyNS0xMi0xOS1lbg==/tiny/Evaxion.png" alt="" original-src="https://ml-eu.globenewswire.com/media/NWMzZjVkMGItOGNiYS00OTgzLTkzN2EtZjAxN2VhMTExNjg4LTEyNjM2NDAtMjAyNS0xMi0xOS1lbg==/tiny/Evaxion.png"/></p>

Evaxion 更新了与 MSD 的合作情况 - 保留淋病疫苗候选产品 EVX-B2 的全球权利 | EVAX 股票新闻